RHO and autosomal dominant retinitis pigmentosa: The Aurora study (NCT04123626), started in 2019, called “A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene”, sponsored by ProQR Therapeutics, is a first-in-human clinical trial designed to assess the safety, tolerability, and preliminary efficacy of QR-1123 in patients with adRP caused by the P23H mutation in the RHO gene.